Celldex Therapeutics reported $-20824000 in Operating Profit for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Abbvie ABBV:US $ 4306M 135M
Amgen AMGN:US $ 2378M 1550M
Applied Genetic Technologies AGTC:US $ -16.42M 2.64M
Aptinyx Inc APTX:US $ -21206000 1.34M
Arena Pharmaceuticals ARNA:US $ -194.48M 50.09M
Biocept BIOC:US $ 0.5M 2.25M
Bristol Myers Squibb BMY:US $ 1996M 281M
Celldex Therapeutics CLDX:US $ -20.82M 7.38M
Cytrx CYTR:US -1532610 351.4K
Glaxosmithkline GSK:US $ 1938M 263M
Immunogen IMGN:US $ -34.23M 6.86M
Merrimack Pharmaceuticals MACK:US $ -886000 121K
Nektar Therapeutics NKTR:US $ -113.6M 3.39M
Newlink Genetics NLNK:US -7497000 1.17M
Northwest Biotherapeutics NWBO:US -10049000 2.49M
Pfizer PFE:US $ 7647M 1733M
Rigel Pharmaceuticals RIGL:US $ -19.78M 6.74M
Seattle Genetics SGEN:US $ -297.96M 208.36M